Literature DB >> 6496557

Potassium and magnesium abnormalities: diuretics and arrhythmias in hypertension.

J W Hollifield.   

Abstract

Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs. Hypokalemia is a commonly encountered metabolic consequence of long-term thiazide therapy but the effect of thiazide on serum magnesium is less well known. Thirty-eight patients (22 low renin, 16 normal renin) with moderate diastolic hypertension were treated with hydrochlorothiazide administered twice a day. The initial daily dose was 50 mg; this was increased at four week intervals to 50 mg, 100 mg, 150 mg, and 200 mg. Dose escalation was discontinued when either normalization blood pressure was attained or the 200 mg dose level was reached. Patients were then maintained with their hydrochlorothiazide dose for 24 weeks of continuous thiazide monotherapy. The serum potassium during the control period was 4.5 +/- 0.2 mmol/liter. During dose escalation and long-term maintenance therapy, the serum potassium and magnesium levels fell in a step wise, dose-dependent fashion. In another 38-patient study, the effects of hydrochlorothiazide therapy (100 mg daily) on the occurrence of premature ventricular contractions were observed during rest as well as during static and dynamic exercise. During rest 0.6 +/- 0.08 premature ventricular contractions per minute (mean +/- SEM) were observed, and during dynamic exercise 0.8 +/- 0.15 premature ventricular contractions per minute. During hydrochlorothiazide therapy (50 or 100 mg per day) premature ventricular contractions per minute were 1.4 and 5.7, respectively. The occurrence of premature ventricular contractions correlated significantly with the decrease observed in serum potassium (r = 0.71, p less than 0.001) and in serum magnesium (r = 0.68, p less than 0.001). Thiazide therapy appears to cause both potassium and magnesium depletion, and decreases in both correlate well with the appearance of ventricular ectopic depolarizations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496557     DOI: 10.1016/s0002-9343(84)80005-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

Review 1.  Risks versus benefits of withdrawing antihypertensive therapy.

Authors:  H P Schobel; R E Schmieder; F H Messerli
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

Review 2.  When is discontinuation of antihypertensive therapy indicated?

Authors:  R E Schmieder; J K Rockstroh
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

3.  Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts.

Authors:  A F Lant
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

4.  A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects.

Authors:  D L Murdoch; G Forrest; D L Davies; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 5.  Diuretic drugs. Progress in clinical pharmacology.

Authors:  A Lant
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 6.  Adverse metabolic effects of antihypertensive drugs. Implications for treatment.

Authors:  H G Preuss; J F Burris
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

7.  Diuretic therapy for hypertension in the elderly.

Authors:  M G Myers
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Potassium loss, ventricular irritability, and the risk of sudden death in hypertensive patients.

Authors:  O B Holland
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Diuretic therapy in congestive heart failure for the elderly patient.

Authors:  E T Carvalho Filho
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.

Authors:  D Maclean; E T Mitchell; R R Coulson; T J Fitzsimons; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.